09.02.2017
Evotec AG DE0005664809
DGAP-Adhoc: Novo A/S becomes new long-term strategic shareholder in Evotec
DGAP-Ad-hoc: Evotec AG / Key word(s): Capital Increase
Novo A/S becomes new long-term strategic shareholder in Evotec
09-Feb-2017 / 21:33 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard,
ISIN: DE 000 566480 9, WKN 566480) today announced that it resolved on a
capital increase from its authorised capital against cash. Evotec will
issue 13,146,019 new shares to Novo A/S (Denmark). Novo A/S is the
independent holding company for the Novo Group.
In this private capital increase, Novo A/S will invest EUR 90.3 m to
subscribe shares of Evotec at a share price of EUR 6.87 per share. The
placement was made at a zero discount to the XETRA closing auction price of
the Evotec stock on 09 February 2017. With the registration of the capital
increase in the commercial register, the share capital of the Company will
increase to EUR 146,197,758.00 or 146,197,758 ordinary bearer shares
respectively.
Evotec will be using the proceeds from the capital increase to accelerate
its focused innovation and roll-up strategy in the outsourcing and external
innovation drug discovery industry.
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred
Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560
81-242, [email protected]
---------------------------------------------------------------------------
09-Feb-2017 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of Announcement DGAP News Service
---------------------------------------------------------------------------
543551 09-Feb-2017 CET/CEST
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT